Recruiting
Phase 3

Eribulin vs. Chemotherapy

Sponsor:

National Cancer Institute (NCI)

Code:

NCT04579224

Conditions

Metastatic Bladder Urothelial Carcinoma

Metastatic Urothelial Carcinoma

Refractory Bladder Urothelial Carcinoma

Refractory Urothelial Carcinoma

Stage IV Bladder Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Scan

Computed Tomography

Docetaxel

Eribulin Mesylate

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-16. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-28.